Australian "swine flu" clinical trial data show no adjuvants tested CSL to use adjuvants when vaccine given

Australian "swine flu" clinical trial data show no adjuvants tested

Last Updated on Saturday, 12 September 2009 12:10



Australian pharmaceutical company CSL's clinical "swine flu" trial data published on September 10th in the New England Journal of Medicine reveals that vaccines without the dangerous adjuvants were used in the clinical trials - even though Australians are set to be given "swine flu" vaccines with adjuvants.

http://content.nejm.org/cgi/content/full/NEJMoa0907413

Also, the trial subjects were healthy adults between the ages of 18 and 64 years old; pregnant women, the elderly and children were, therefore, excluded - even though these are the priority groups for the "swine flu" vaccine.

Furthermore, the trials appear to be conducted on the only one of the WHO candidate vaccines that was not engineered by reverse genetics.

http://www.who.int/csr/resources/publications/swineflu/summary_candidate_vaccine.pdf

http://www.who.int/csr/resources/publications/swineflu/ivr153_20090608_en.pdf

The report in the NEJM states:

"The H1N1 vaccine, a monovalent, unadjuvanted, inactivated, split-virus vaccine, was produced by CSL Biotherapies (Parkville, Australia). The seed virus was prepared from the reassortant vaccine virus NYMC X-179A (New York Medical College, New York), derived from the A/California/7/2009 (H1N1) virus, one of the candidate reassortant vaccine viruses recommended by the WHO.8,9



"Healthy, nonpregnant adults between the ages of 18 and 64 years were eligible for enrollment."

What relevance does this clinical data have to the actual vaccines that will be given to Australians when a key ingredient -- and a huge body of scientific evidence exists to show adjuvants are dangerous -- is excluded as are key target groups?